J Clin Med Res

Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access

Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc

Journal website http://www.jocmr.org

Short Communication

Volume 11, Number 4, April 2019, pages 297-300

Differing Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Ipragliflozin on the Decrease of Fat Mass vs. Lean Mass in Patients With or Without Metformin Therapy

Figure

Figure 1. Changes of fat mass and lean mass assessed by dual energy X-ray absorptiometry during the 24-week study period.

Table

**Table 1.** Baseline Characteristics of the Subgroups Receiving Ipragliflozin Alone or With Metformin
	Ipragliflozin alone (n = 9)	Ipragliflozin with metformin (n = 11)	P value
Data are expressed as the mean ± standard deviation for continuous variables or as the median (IQR). Categorical variables are expressed as numbers. eGFR: estimated glomerular filtration rate; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; DPP-4: dipeptidyl peptidase-4; GLP-1: glucagon-like peptide-1; IQR: interquartile range.
Women	3	6	0.369
Age (years)	53 ± 10	51 ± 7	0.626
Body weight (kg)	82.5 ± 7.9	81.9 ± 13.9	0.915
Body mass index (kg/m²)	29 ± 2.3	30.2 ± 3.8	0.416
Duration of diabetes (years)	3 (1 - 6)	8 (6.5 - 12)	0.079
Fasting plasma glucose (mg/dL)	161 ± 17	181 ± 50	0.288
Hemoglobin A1c (%)	8.0 ± 1.4	8.4 ± 1.3	0.502
Systolic blood pressure (mm Hg)	139 ± 11	130 ± 17	0.207
Diastolic blood pressure (mm Hg)	82 ± 12	80 ± 15	0.767
eGFR (mL/min/1.73 m²)	88 ± 11	92 ± 11	0.437
LDL-C (mg/dL)	127 ± 22	105 ± 27	0.057
HDL-C (mg/dL)	50 ± 11	46 ± 7	0.373
Triglycerides (mg/dL)	118 ± 51	114 ± 48	0.055
Lactate (mmol/L)	1.1 ± 0.4	1.6 ± 0.4	0.027
Medications (n)
Sulfonylurea	3	4
Thiazolidinedione	1	2
α-Glucosidase inhibitor	0	4
DPP-4 inhibitor	3	4
Insulin	4	4
GLP-1 receptor agonist	0	4